-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Head to Head Review: Cerus (NASDAQ:CERS) & Longview Acquisition Corp. II (NYSE:LGV)
Head to Head Review: Cerus (NASDAQ:CERS) & Longview Acquisition Corp. II (NYSE:LGV)
Longview Acquisition Corp. II (NYSE:LGV – Get Rating) and Cerus (NASDAQ:CERS – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings and risk.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Longview Acquisition Corp. II and Cerus, as reported by MarketBeat.
Get Longview Acquisition Corp. II alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Longview Acquisition Corp. II | 0 | 0 | 0 | 0 | N/A |
Cerus | 0 | 2 | 1 | 0 | 2.33 |
Cerus has a consensus target price of $4.88, suggesting a potential upside of 61.96%. Given Cerus' higher probable upside, analysts plainly believe Cerus is more favorable than Longview Acquisition Corp. II.
Institutional and Insider Ownership
66.3% of Longview Acquisition Corp. II shares are owned by institutional investors. Comparatively, 82.5% of Cerus shares are owned by institutional investors. 26.4% of Longview Acquisition Corp. II shares are owned by insiders. Comparatively, 7.3% of Cerus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.Valuation and Earnings
This table compares Longview Acquisition Corp. II and Cerus' top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Longview Acquisition Corp. II | N/A | N/A | $7.40 million | N/A | N/A |
Cerus | $130.86 million | 4.08 | -$54.38 million | ($0.22) | -13.68 |
Longview Acquisition Corp. II has higher earnings, but lower revenue than Cerus.
Risk & Volatility
Longview Acquisition Corp. II has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Cerus has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.
Profitability
This table compares Longview Acquisition Corp. II and Cerus' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Longview Acquisition Corp. II | N/A | -65.52% | 3.65% |
Cerus | -24.24% | -48.32% | -17.18% |
Summary
Cerus beats Longview Acquisition Corp. II on 6 of the 10 factors compared between the two stocks.
About Longview Acquisition Corp. II
(Get Rating)
Longview Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on businesses in the healthcare, industrials, consumer, media, technology, and technology services sector. The company was incorporated in 2020 and is based in New York, New York.
About Cerus
(Get Rating)
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
Receive News & Ratings for Longview Acquisition Corp. II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longview Acquisition Corp. II and related companies with MarketBeat.com's FREE daily email newsletter.
朗维尤收购公司II(NYSE:LGV-GET Rating)和Cerus(纳斯达克:CERS-GET Rating)都是小盘医疗公司,但哪一家是优势业务?我们将根据这两家公司的股息实力、机构所有权、估值、盈利能力、分析师建议、收益和风险进行比较。
分析师评级
据MarketBeat报道,这是对Longview Acquisition Corp.II和Cerus最近评级和推荐的摘要。
到达朗维尤收购公司II警报:销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
朗维尤收购公司II | 0 | 0 | 0 | 0 | 不适用 |
谷神星 | 0 | 2. | 1 | 0 | 2.33 |
Cerus的共识目标价为4.88美元,暗示潜在上行空间为61.96%。考虑到Cerus的上行可能性更高,分析师们显然认为Cerus比Longview收购公司II更有利。
机构和内部人持股
Longview Acquisition Corp.II的66.3%股份由机构投资者持有。相比之下,Cerus 82.5%的股份由机构投资者持有。Longview Acquisition Corp.II的26.4%股份由内部人士持有。相比之下,Cerus 7.3%的股份由内部人士持有。强大的机构持股表明,捐赠基金、对冲基金和大型基金管理公司相信,一家公司的长期表现将好于大盘。估值和收益
此表比较了Longview Acquisition Corp.II和Cerus的营收、每股收益(EPS)和估值。
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
朗维尤收购公司II | 不适用 | 不适用 | 740万美元 | 不适用 | 不适用 |
谷神星 | 1.3086亿美元 | 4.08 | -5438万美元 | (0.22美元) | -13.68 |
Longview Acquisition Corp.II的收益高于Cerus,但营收低于Cerus。
风险与波动性
Longview Acquisition Corp.II的贝塔系数为0.04,这意味着其股价的波动性比标准普尔500指数低96%。相比之下,Cerus的贝塔系数为1.09,这意味着其股价的波动性比标准普尔500指数高出9%。
盈利能力
此表比较了Longview收购公司II和Cerus的净利润率、股本回报率和资产回报率。
净利润率 | 股本回报率 | 资产回报率 | |
朗维尤收购公司II | 不适用 | -65.52% | 3.65% |
谷神星 | -24.24% | -48.32% | -17.18% |
摘要
Cerus在比较两只股票的10个因素中有6个超过了Longview Acquisition Corp.II。
关于Longview收购公司II
(获取评级)
Longview Acquisition Corp.II没有重大业务。拟与一家或多家企业进行合并、资本换股、资产收购、股票购买、重组或类似的业务合并。该公司打算专注于医疗保健、工业、消费者、媒体、技术和技术服务部门的业务。该公司成立于2020年,总部设在纽约。
关于Cerus
(获取评级)
Cerus Corp.从事生物医学和外科产品的研究、开发和制造。该公司生产用于血小板和血浆的血液系统。它通过血液安全部门运作。它以Intercept品牌营销产品。该公司由劳伦斯·M·科拉什和约翰·E·赫斯特于1991年9月19日创立,总部设在加利福尼亚州康科德。
接受Longview收购公司的新闻和评级II Daily-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Longview Acquisition Corp.II和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧